Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Wuhan YZY Biopharma CoHKSE:02496 EBIT per Share is HK$-0.45 as of Dec. 2025. The stock has 8 warning signs investors should review. Among 1,168 Biotechnology companies, Wuhan YZY Biopharma Co ranks better than 62.33% on this metric.
Wuhan YZY Biopharma Co's EBIT per Share for the
six
months ended in Dec. 2025 was HK$-0.13.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-0.45.
During the past 3 years, the average EBIT per Share Growth Rate was 24.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Wuhan YZY Biopharma Co's EBIT per Share or its related term are showing as below:
HKSE:02496'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 14.2 Med: 19.55 Max: 24.9
Current: 24.9
During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Wuhan YZY Biopharma Co was 24.90% per year. The lowest was 14.20% per year. And the median was 19.55% per year.
HKSE:02496's 3-Year EBIT Growth Rate is ranked better than 62.33% of 1168
companies
in the Biotechnology industry
Industry Median: 15.45
vs HKSE:02496: 24.90
Wuhan YZY Biopharma Co (HKSE:02496) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Wuhan YZY Biopharma Co EBIT per Share Related Terms
Wuhan YZY Biopharma Co EBIT per Share Historical Data
* Premium members only.
The historical data trend for Wuhan YZY Biopharma Co's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.45
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wuhan YZY Biopharma Co (HKSE:02496) has a EBIT per Share of HK$-0.45 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Wuhan YZY Biopharma Co and its competitors. According to the industry distribution chart, Wuhan YZY Biopharma Co ranks #440 out of 1168 companies in the Biotechnology industry, placing it in the top 37.7%.
Is Wuhan YZY Biopharma Co's EBIT per Share too high?
Wuhan YZY Biopharma Co's current EBIT per Share is HK$-0.45. Based on the distribution chart, Wuhan YZY Biopharma Co ranks #440 out of 1168 companies in the Biotechnology industry, which is above the industry midpoint.
How does Wuhan YZY Biopharma Co's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Wuhan YZY Biopharma Co ranks #440 out of 1168 companies for EBIT per Share. This puts Wuhan YZY Biopharma Co in the upper half of its industry. The industry median EBIT per Share is 15.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.45, based on 1,168 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Wuhan YZY Biopharma Co and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wuhan YZY Biopharma Co's current EBIT per Share is HK$-0.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuhan YZY Biopharma Co stock overvalued right now?
Wuhan YZY Biopharma Co (HKSE:02496) has a current EBIT per Share of HK$-0.45. The current EBIT per Share is HK$-0.45. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Wuhan YZY Biopharma Co (HKSE:02496), the current EBIT per Share is HK$-0.45 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Wuhan YZY Biopharma Co Ltd is a biotechnology company dedicated to developing bispecific antibody (BsAb)- based therapies. The Company has been forward-looking in deploying its presence in several therapeutic fields, including but not limited to tumor-associated complications, tumors, ophthalmology, and autoimmune diseases. The Company also proactively established several self-developed technology platforms, such as Y-BODY, Check-Body, and Nano-Ybody, promoting the development of more candidates to clinical stages with high efficiency.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02496 has been successfully added to your 
